TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06758830

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy (RT) is administered at a dose of 2 Gy per day for a total dose of 50 Gy delivered to the pelvis. This is done throughout 5 to 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Capecitabine: 825 mg/m² twice daily, prescribed 1-5 days per week, for 5 weeks during RT.~Or Bolus 5-FU regimen: 5-fluorouracil (5-FU) 400 mg/m2/day intravenously, administered on days 1-4 and 33-35. Calcium folinate (folinic acid) 20 mg/m2/day intravenously on days 1-4 and 33-35.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation Chemotherapy
Description: XELOX: Oxaliplatin 130 mg/m² (day 1) + capecitabine 1000 mg/m² (days 1-14), every 3 weeks for 4 cycles.~Or FOLFOX: Oxaliplatin - 85 mg/m2 intravenously (2-hour infusion), drip for 1 day. Calcium folinate (folinic acid) - 400 mg/m2/d. intravenously (2-hour infusion), started on day 1. F(5-fluorouracil) - 400 mg/m2/d. intravenously (bolus), started on day 1. Repeat every 2 weeks for 6 times.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Transabdominal Resection: Abdominoperineal resection, low anterior resection, or coloanal anastomosis using total mesorectal excision.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Transabdominal Resection: Abdominoperineal resection, low anterior resection, or coloanal anastomosis using total mesorectal excision.

Intervention type: OTHER
Group type: OTHER
Intervention: Part two
Description: Standard treatment protocols and follow-up procedures are implemented in clinical practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant treatment
Description: If indicated, adjuvant therapy will be administered as usual in clinical practice.
Study: NCT06760234

Intervention type: DIAGNOSTIC_TEST
Intervention: No Interventions
Description: The high-throughput extraction of quantitative image features from medical images

Intervention type: DIAGNOSTIC_TEST
Intervention: No Interventions
Description: The high-throughput extraction of quantitative image features from medical images

Intervention type: DIAGNOSTIC_TEST
Intervention: No Interventions
Description: Immunohistochemical analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: No Interventions
Description: Immunohistochemical analysis
Study: NCT06766058

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Carrier oil
Description: Inhaler stick containing 2 drops of carrier oil.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asian plant extract blend
Description: Inhaler stick containing 2 drops of Asian plant extract blend.
Study: NCT06766136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma education program
Description: An educational program based on the Roy Adaptation Model in addition to standard asthma treatment.
Study: NCT06766799

Intervention type: DEVICE
Intervention: Rebound and Applanation Tonometer
Description: Measurement of Intraocular Pressure

Intervention type: DEVICE
Intervention: Rebound and Applanation Tonometer
Description: Measurement of Intraocular Pressure
Study: NCT06765200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-administered psychosocial intervention delivered via smartphone.
Description: The treatment includes a smartphone-based psychosocial program designed to improve the quality of life of adolescents with chronic pain.
Study: NCT06766864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-01
Description: DR-01 is a monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-01
Description: DR-01 is a monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-01
Description: DR-01 is a monoclonal antibody

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06765785

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CTCA
Description: Screening CTCA will be performed in the experimental arm after 1:1 randomisation using sealed envelope technique
Study: NCT06766656

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision
Description: The pocket for the vascular port is made through a small incision in the skin in the subclavicular area. The skin incision can be made transversely or longitudinally

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision
Description: The pocket for the vascular port is made through a small incision in the skin in the subclavicular area. The skin incision can be made transversely or longitudinally
Study: NCT06765356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Farapulse Catheter System
Description: The FARAWAVE PFA Catheter is a sterile, single use, over-the-wire, non-deflectable device that is used with the FARASTAR Catheter Connection Cable and FARASTAR Generator to enable delivery of Pulsed Field Ablation energy for irreversible electroporation. The FARAWAVE PFA Catheter has five (5) variably deployable splines. The five splines are undeployed during insertion and removal and during use can deploy continuously from an undeployed state through a partially deployed (basket-shaped) configuration to a fully deployed (flower-shaped) configuration with five petals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose Colchicine
Description: For participants in the colchicine sub-study, 0.3 mg BID Colchicine. Colchicine will be prescribed to the patient starting 5 days prior to ablation. Patient will continue the colchicine for 3 weeks post-ablation.
Study: NCT06765707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist delivered symptom monitoring and management
Description: Patients in the intervention phase will receive PRO-based symptom monitoring once a month and pharmacist-led management for problematic symptoms based on routine clinical care recommendations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist delivered symptom monitoring and management
Description: Patients in the intervention phase will receive PRO-based symptom monitoring once a month and pharmacist-led management for problematic symptoms based on routine clinical care recommendations.
Study: NCT06767150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: a second infusion of ZOL when crosslaps levels reach 300 pg/mL
Description: a first infusion of ZOL 5 mg, 6 months after denosumab withdrawal (= study start) and a second infusion when crosslaps levels reach 300 pg/mL, no later than month-12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: a rescue second infusion at month-12 (standard traitment)
Description: a first infusion of ZOL 5 mg, 6 months after denosumab withdrawal (= study start), and potentially a rescue second infusion at month-12, in case unfavourable outcome (incident osteoporotic fractures) or high risk of unfavourable outcome
Study: NCT06765343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plaque disclosing agent
Description: Dye agent binding to oral biofilm and plaque for visual detection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plaque disclosing agent
Description: Dye agent binding to oral biofilm and plaque for visual detection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guided Biofilm Therapy
Description: Utilisation of a air-polishing device conveying a jet of air, water and erythritol powder for plaque debridement on dental surfaces, followed by calculus removal with an ultrasonic scaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guided Biofilm Therapy
Description: Utilisation of a air-polishing device conveying a jet of air, water and erythritol powder for plaque debridement on dental surfaces, followed by calculus removal with an ultrasonic scaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic debridement and polishing
Description: Removal of plaque and calculus with an ultrasonic scaler, followed by surface polishing with a rubber cup and abrasive paste

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic debridement and polishing
Description: Removal of plaque and calculus with an ultrasonic scaler, followed by surface polishing with a rubber cup and abrasive paste
Study: NCT06766838

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1. Conventional dissection technique (group A) :
Description: In this group, circumcision is performed by the dorsal slit technique. A slit is made dorsally to the level of about 5 mm from the coronal sulcus, and the redundant foreskin and mucosa were excised circumferentially. Hemostasis is secured with ligation , and the cut edges are sutured with absorbable suture. Then, dressing is applied.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2. Bone cutting forceps technique (Group B)
Description: Two mosquito forceps are used to grasp the foreskin. The glans penis is squeezed back to avoid its injury. After that, bone cutting forceps is applied to the foreskin for 3 minutes, at the level of the mark, then the foreskin is excised by scalpel at the same level. Bleeding points are ligated and the cut edges are sutured with absorbable suture. Then, a dressing is applied

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3. Electro-cauterization (bipolar) assisted circumcision (Group C)
Description: The skin is held by two hemostats to elevate the foreskin, and then the kocher clamp applied at the level of the skin to be removed for circumcision. Excess foreskin will be cut by scissor with hemostasis by bipolar cauterization.~The skin retracted proximally after that to expose the glans. Sutures are made if there is separation between the skin and the mucous membrane.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 4. Thermal cauterization assisted circumcision (Group D)
Description: The skin is held by two hemostats to elevate the foreskin, and then the kocher clamp applied at the level of the skin to be removed for circumcision. Excess foreskin will be cut by thermal cauterization. The skin retracted proximally after that to expose the glans. Sutures are made if there is separation between the skin and the mucous membrane.
Study: NCT03846830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incremental Velocity Error (IVE)
Description: A lightweight headband has electronics attached that detect head velocity and move a laser target at a fraction of the head velocity.
Study: NCT06766838

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 5. Gomco clamp technique (Group E):
Description: The prepuce is grasped using two hemostats applied at 2 and 10 o'clock. A dorsal slit at 12 o'clock is made, appropriate-sized bell is placed over the glans, and the foreskin is brought over its top. The string is placed around the foreskin and the Plastibell device at the level of the mark in a groove that acted as the string placement guide. The string is then tightened and tied in a simple square knot. The excess foreskin is trimmed from around the bell using iris scissors. The handle is then broken off the device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 6. Plastibell device technique (Group F):
Description: The prepuce is grasped using two hemostats applied at 2 and 10 o'clock. A dorsal slit at 12 o'clock is made, appropriate-sized bell is placed over the glans, and the foreskin is brought over its top. The string is placed around the foreskin and the Plastibell device at the level of the mark in a groove that acted as the string placement guide. The string is then tightened and tied in a simple square knot. The excess foreskin is trimmed from around the bell using iris scissors. The handle is then broken off the device
Study: NCT06766968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graduated Compression Stocking: 1 month using
Description: Class 2 (RAL-GZ 387 standard: 23-32 mm Hg at the ankle level) above-knee graduated compression stockings

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Graduated Compression Stocking: 1 week using
Description: Class 2 (RAL-GZ 387 standard: 23-32 mm Hg at the ankle level) above-knee graduated compression stockings
Study: NCT06765512

Intervention type: OTHER
Intervention: use of deep learning and automated machine learning to diagnose and classify adenomyosis
Description: Vertex AI Vision V1 software will be used as an automated machine learning tool and Pytorch 2.5 as deep learning framework. The complete set of reviewed, formatted and labelled images will be uploaded and split manually into two different datasets in 9:1 ratio; 90% of the selected images will be used as training dataset (training + validation) and 10% as test dataset.
Study: NCT06765499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chinese medicine - Silkworm pupa powder
Description: Silkworm pupa contains high-quality animal protein and has a wide range of activities in antioxidant, antitumor, antibacterial, and immune enhancement, making it highly nutritious and medicinally valuable.
Study: NCT03846830

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Incremental Velocity Error (IVE)
Description: A lightweight headband has electronics attached that detect head velocity and move a laser target at a fraction of the head velocity.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Incremental Velocity Error (IVE)
Description: A lightweight headband has electronics attached that detect head velocity and move a laser target at a fraction of the head velocity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Vestibular Rehabilitation (VPT)
Description: Standard of care, meta-analysis vetted, eye and head motion exercises to reduced morbidity associated with dizziness and imbalance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Vestibular Rehabilitation (VPT)
Description: Standard of care, meta-analysis vetted, eye and head motion exercises to reduced morbidity associated with dizziness and imbalance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Vestibular Rehabilitation (VPT)
Description: Standard of care, meta-analysis vetted, eye and head motion exercises to reduced morbidity associated with dizziness and imbalance.
Study: NCT06405828

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACCESS Supportive Care
Description: ACCESS Supportive Care includes:~1. Coaching sessions: 6 one-hour weekly Community Navigator led supportive and early palliative care health coaching sessions. Sessions will be hybrid (in-person or virtual) per participant preference.~2. Monthly check-in: Monthly check-ins (\~5-10 minutes) about their supportive care and social determinants of health needs over 16 weeks.~3. Scheduling of outpatient supportive oncology appointment if interested.~4. Community linkage: Warm hand offs and connection to community resources to enhance access to support groups, educational workshops, and healthy lifestyle services.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Phone sessions
Description: 6 weekly phone sessions, approximately 10 minutes in length each, to review breast cancer and supportive and palliative care resources in NYC and online. The 6 weekly phone sessions will include the topics discussed in the intervention arm but will be informational in nature. The phone sessions will be followed by monthly check-ins (\~5 minutes) to review and answer questions about the resources for the duration of 16 weeks.
Study: NCT04429555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibudilast
Description: 50 mg (5 x 10 mg capsules) twice daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg (5 matching capsules) twice daily for 7 days
Study: NCT06765499

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ultra-low dose silkworm pupa powder
Description: 0.5% of the effective components in the experimental group
Study: NCT06766331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated care
Description: Receipt of infectious diseases laboratory testing and/or PrEP for HIV within a single substance use disorder clinic appointment.
Study: NCT06765876

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CAR123 T lymphocytes
Description: Anti-CD123 Chimeric Antigen Receptor (CAR) T-Cells (CART123)
Study: NCT06767813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2868 injection+Gemcitabine injection+ Albumin paclitaxel injection+ Anlotinib capsules
Description: TQB2868 injection is an anti-PD 1/growth factor (GF)-β Receptor Type II (TGF-βRII) bifunctional fusion protein.
Study: NCT06766162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality pain distraction
Description: The intervention group in this study will undergo their ESD procedure with the addition of virtual reality (VR) as a supportive tool. Participants in this group will use a VR headset during the procedure, designed to provide an immersive experience that may help manage pain and anxiety. The use of VR will be integrated alongside the standard care protocol, including routine sedation and pain management practices VR headset is from DRVR, Rescope innovation which is registered as medical device in the UK.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard analgesia and sedation
Description: Standard local protocol for analgesia and sedation, incorporating fentanyl and midazolam.
Study: NCT06762860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: label sticker

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron
Description: label sticker

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: label sticker
Study: NCT06765915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: After allo-HSCT, CBF-AML patients who have kit mutation would receive avapritinib for maintenance therapy.
Study: NCT06766760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Da Vinci SP Surgical System, Model SP1098
Description: The da Vinci SP Surgical System is intended to assist in the accurate control of the da Vinci SP endoscope and instruments during minimally invasive endoscopic abdominopelvic, thoracoscopic, transoral otolaryngology, and breast surgical procedures. The system is indicated for adult use. It is intended to be used by trained physicians in an operating room environment.
Study: NCT06766929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSA012
Description: subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection
Study: NCT06767176

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training
Description: 7 doses, taken daily, 70 ml shots, consumed in the morning before the start of fasting
Study: NCT06766565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QYJD Compound Preparation
Description: The intervention group was treated with 2 capsules (g) of expelling stasis and QYJD compound preparation orally for 4 days before thoracoscopic radical surgery for lung cancer, 3 times a day. The blank control group had no oral drug treatment before surgery.
Study: NCT06765720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent feeding method with nasogastric tube
Description: 30 Minutes Before Feeding: No invasive procedures will be performed 30 minutes before the daily 1:00 PM feeding.~5 Minutes Before Feeding: To measure physiological variables, the pulse oximeter probe will be attached to the baby's foot. Oxygen saturation and heart rate will be measured for 2 minutes before feeding.~Feeding Phase: Measurement values will be taken from the pulse oximeter during feeding.~Post-Feeding Phase: Any interventions that could affect physiological values will be prevented, and oxygen saturation and heart rate will continue to be measured during the 2-minute period. The baby will be scored using the Early Feeding Skills Assessment Tool.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent feeding method with orogastric tube
Description: 30 Minutes Before Feeding: No invasive procedures will be performed 30 minutes before the daily 1:00 PM feeding.~5 Minutes Before Feeding: To measure physiological variables, the pulse oximeter probe will be attached to the baby's foot. Oxygen saturation and heart rate will be measured for 2 minutes before feeding.~Feeding Phase: Measurement values will be taken from the pulse oximeter during feeding.~Post-Feeding Phase: Any interventions that could affect physiological values will be prevented, and oxygen saturation and heart rate will continue to be measured during the 2-minute period. The baby will be scored using the Early Feeding Skills Assessment Tool.
Study: NCT06768047

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microporous tape
Description: Microporous tape is a dressing tape that was discovered to have scar modulating effects. It is made up of a conformable, inextensible, nonwoven fabric manufactured from 100% viscose and coated with a layer of acrylic adhesive. It is cheap, cost-effective, readily available, and relatively affordable for post surgical patients.

Intervention type: OTHER
Group type: OTHER
Intervention: Tradition physical therapy
Description: Tradition physical therapy as stretching exercises and deep friction massage, Stretching is a form of physical exercise in which a specific muscle or tendon (or muscle group) is deliberately expanded and flexed in order to improve the muscle's felt elasticity and achieve comfortable muscle tone. The result is a feeling of increased muscle control, flexibility, and range of motion.~Deep friction massage also known as cross friction massage, is a specific connective tissue massage which maintain the mobility within the soft tissue structures of ligament, tendon, and muscle, and prevent adherent scars from forming.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tradition physical therapy
Description: Tradition physical therapy as stretching exercises and deep friction massage, Stretching is a form of physical exercise in which a specific muscle or tendon (or muscle group) is deliberately expanded and flexed in order to improve the muscle's felt elasticity and achieve comfortable muscle tone. The result is a feeling of increased muscle control, flexibility, and range of motion.~Deep friction massage also known as cross friction massage, is a specific connective tissue massage which maintain the mobility within the soft tissue structures of ligament, tendon, and muscle, and prevent adherent scars from forming.